PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-6.24%
Cash & equivalents declining -6.24% while Medical - Pharmaceuticals shows -1.40% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
-6.24%
Below half the Medical - Pharmaceuticals median of 0.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
-99.40%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
0.08%
Inventory growth less than half of Medical - Pharmaceuticals median of 1.05%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
45.42%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-1.00%
Near the Medical - Pharmaceuticals median of -1.00%. Charlie Munger sees typical short-term asset management among peers.
3.99%
PP&E growth below half of Medical - Pharmaceuticals median of -1.26%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
-10.63%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-10.63%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
12.19%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-7617.89%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
1065.65%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.48%
≥ 1.5x the Medical - Pharmaceuticals median of 0.05%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
-50.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
1.93%
Below half the Medical - Pharmaceuticals median of -0.35%. Jim Chanos might see potential stagnation or distress vs. peers.
5.72%
Payables growth 1.1-1.25x Medical - Pharmaceuticals median of 4.63%. John Neff wonders if the company is pushing out payments more than peers.
-0.02%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-53.96%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-81.59%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
517.96%
Below half Medical - Pharmaceuticals median of -1.19%. Joel Greenblatt sees fewer expansions than peers.
1.62%
1.1-1.25x Medical - Pharmaceuticals median of 1.35%. John Neff wonders if liabilities are rising faster than peers.
-12.27%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
145.07%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-6.50%
Above 1.5x Medical - Pharmaceuticals median of -0.48%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
0.51%
Below half Medical - Pharmaceuticals median of -0.40%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
4.82%
Below half Medical - Pharmaceuticals median of -0.19%. Jim Chanos suspects poor profitability or large dividend drains.
20.00%
Above 1.5x Medical - Pharmaceuticals median 12.79%. Jim Chanos suspects a red flag if these gains are highly volatile.
100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
4.20%
≥ 1.5x Medical - Pharmaceuticals median of 0.46%. Joel Greenblatt sees stronger equity growth vs. peers.
1.93%
Below half Medical - Pharmaceuticals median of -0.35%. Jim Chanos suspects a major slowdown or distress.
52767.74%
≥ 1.5x Medical - Pharmaceuticals median of 0.49%. Joel Greenblatt sees bigger push into investments vs. peers.
-34.68%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-317.26%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.